CHICAGO, Illinois — An investigational oral synthetic androgen shows promise as a possible male contraceptive pill in a new month-long study. Dose-finding and safety results of the trial in 82 healthy men were presented March 18 here ENDO 2018: The Endocrine Society Annual Meeting by Arthi Thirumalai, MBBS, acting assistant professor, University of Washington, Seattle. "It only needs to be dosed once a day, and we didn't see any significant side effects, but it needs to be tested much longer. This is a very early phase," Study coauthor Stephanie Page, MD, PhD, professor of medicine at the university, told Medscape Medical News. The agent, dimethandrolone undecanoate (DMAU), is a prodrug that is converted to dimethandrolone (DMA), which binds to both androgen and progesterone receptors. The long-chain fatty acid component undecanoate slows the drug's clearance, enabling the once-daily dosing. During a press briefing, Page showed data from a multinational surv
Comments